Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PRF1 | P14222 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL539978 | 0.88 | KDM4E (0.33) | KDM4EPKMALDH1A1MEN1LMNA | |
| SCHEMBL21918985 | 0.80 | KDM4E (0.42) | KDM4EPKMALDH1A1MEN1LMNA | |
| SCHEMBL14612384 | 0.78 | KDM4E (0.41) | KDM4EPKMALDH1A1MEN1LMNA | |
| SCHEMBL2654567 | 0.78 | KDM4E (0.45) | KDM4EPKMALDH1A1MEN1LMNA | |
| Hydrochloric Acid SCHEMBL27764055 | 0.77 | KDM4E (0.44) | KDM4EPKMALDH1A1MEN1LMNA | |
| SCHEMBL30276878 | 0.75 | KDM4E (0.38) | KDM4EPKMALDH1A1MEN1LMNA | |
| SCHEMBL31664536 | 0.75 | KDM4E (0.38) | KDM4EPKMALDH1A1MEN1LMNA | |
| SCHEMBL415794 | 0.72 | KDM4E (0.36) | KDM4EPKMALDH1A1MEN1LMNA | |
| SCHEMBL25271998 | 0.70 | — | — | |
| SCHEMBL25272296 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| EP-2643299-B1 | BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS | NOSCIRA SA (ES) | 2016-06-22 | — | — | EP | disclosed |
| CN-101460223-A | Quinolones as Inducible Nitric Oxide Synthase Inhibitors | KALYPSYS INC (US) | 2009-06-17 | — | — | CN | disclosed |
| WO-2007117778-A9 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS INC (US) | 2009-05-22 | — | — | WO | disclosed |
| EP-1986747-A2 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | Kalypsys, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008103615-A1 | ISOQUINOLINES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20080139558-A1 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139558-A1 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139558-A1 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2007117778-A2 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117778-A2 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139558-A1 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | NOS2, NOS1, NQO2 | KDM4E 3053/4885PKM 3495/4885ALDH1A1 1044/4885 |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | KDM4E 1188/4885PKM 1092/4885ALDH1A1 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.